Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 8/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | ATR | Q13535 | 4/20 | 0.45 |
| ▸ | PRKDC | P78527 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493672 | 0.91 | NR1H2 (0.66) | NR1H2NR1H3PARP1SYK | |
| SCHEMBL2358915 | 0.83 | POLB (0.45) | NR1H2NR1H3PARP1 | |
| SCHEMBL3491488 | 0.81 | NR1H2 (0.66) | NR1H2NR1H3ATR | |
| SCHEMBL2317820 | 0.80 | BCHE (0.56) | PARP1 | |
| SCHEMBL2320964 | 0.80 | NR1H2 (0.62) | NR1H2NR1H3 | |
| SCHEMBL2358913 | 0.78 | NR1H2 (0.45) | NR1H2NR1H3PARP1 | |
| SCHEMBL3492028 | 0.78 | NR1H2 (0.83) | NR1H2NR1H3KIF11PTGS2PTGS1 | |
| SCHEMBL16566189 | 0.74 | NR1H2 (0.58) | NR1H2NR1H3 | |
| SCHEMBL2359417 | 0.74 | ALOX5AP (0.46) | NR1H2NR1H3PTGS2 | |
| SCHEMBL3490740 | 0.74 | NR1H2 (0.83) | NR1H2NR1H3KIF11SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010054229-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH LLC (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885KCNH2 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.